000			03960nam a22007097a 4500
008			210607s20212021 xxu||||| |||| 00| 0 eng d
022			_a2352-3964
024			_a10.1016/j.ebiom.2021.103279 [doi]
024			_aPMC8010619 [pmc]
024			_aS2352-3964(21)00072-4 [pii]
040			_aOvid MEDLINE(R)
099			_a33752126
245			_aPlasma epoxyeicosatrienoic acids and dihydroxyeicosatrieonic acids, insulin, glucose and risk of diabetes: The strong heart study.
251			_aEBioMedicine. 66:103279, 2021 Apr.
252			_aEBioMedicine. 66:103279, 2021 Apr.
252			_zEBioMedicine. 66:103279, 2021 Mar 19.
253			_aEBioMedicine
260			_c2021
260			_fFY2021
265			_saheadofprint
265			_sppublish
266			_d2021-06-07
268			_aEBioMedicine. 66:103279, 2021 Mar 19.
269			_fFY2021
520			_aBACKGROUND: Epoxyeicosatrienoic acids (EETs) are metabolites of arachidonic acid with multiple biological functions. Rodent experiments suggest EETs play a role in insulin sensitivity and diabetes, but evidence in humans is limited. To address this knowledge gap, we conducted a case-cohort study in the Strong Heart Family Study, a prospective cohort among American Indians.
520			_aFINDINGS: We observed no significant association of total EET or DHET levels with incident diabetes. In addition, plasma EETs were not associated with plasma insulin or plasma glucose. However, higher plasma 14,15-DHET was associated with lower plasma insulin and lower plasma glucose.
520			_aFUNDING: US National Institutes of Health. Copyright (c) 2021 The Authors. Published by Elsevier B.V. All rights reserved.
520			_aINTERPRETATION: In this first prospective study of EETs and diabetes, we found no evidence for a role of total plasma EETs in diabetes. The novel associations of 14,15-DHET with insulin and glucose warrant replication and exploration of possible mechanisms.
520			_aMETHODS: We measured 4 EET species and 4 species of corresponding downstream metabolites, dihydroxyeicosatrieonic acids (DHETs), in plasma samples from 1161 participants, including 310 with type 2 diabetes. We estimated the associations of total (esterified and free) EETs and DHETs with incident diabetes risk, adjusting for known risk factors. We also examined cross-sectional associations with plasma fasting insulin and glucose in the case-cohort and in 271 participants without diabetes from the older Strong Heart Study cohort, and meta-analyzed the results from the 2 cohorts.
546			_aEnglish
650			_a*8,11,14-Eicosatrienoic Acid/bl [Blood]
650			_a*Biomarkers/bl [Blood]
650			_a*Blood Glucose
650			_a*Diabetes Mellitus, Type 2/et [Etiology]
650			_a*Diabetes Mellitus, Type 2/me [Metabolism]
650			_a*Insulin/bl [Blood]
650			_a8,11,14-Eicosatrienoic Acid/aa [Analogs & Derivatives]
650			_aAdolescent
650			_aAdult
650			_aAged
650			_aAged, 80 and over
650			_aCase-Control Studies
650			_aCross-Sectional Studies
650			_aDiabetes Mellitus, Type 2/bl [Blood]
650			_aDiabetes Mellitus, Type 2/ep [Epidemiology]
650			_aDisease Susceptibility
650			_aFemale
650			_aGlucose/me [Metabolism]
650			_aHumans
650			_aMale
650			_aMiddle Aged
650			_aRisk Assessment
650			_aRisk Factors
650			_aYoung Adult
651			_aMedStar Health Research Institute
657			_aJournal Article
700			_aHoward, Barbara V
700			_aUmans, Jason G
790			_aDenham J, Fretts AM, Gharib SA, Howard BV, Jensen PN, King IB, Lemaitre RN, McKnight B, Psaty BM, Siscovick DS, Sitlani CM, Sotoodehnia N, Totah RA, Umans JG, Zeigler M
856			_uhttps://dx.doi.org/10.1016/j.ebiom.2021.103279 _zhttps://dx.doi.org/10.1016/j.ebiom.2021.103279
942			_cART _dArticle
999			_c6302 _d6302